Infantile leukemia-What factors determine its distinct biological nature? Clinicopathological study of 78 cases

Int J Lab Hematol. 2021 Oct;43(5):1117-1122. doi: 10.1111/ijlh.13540. Epub 2021 Apr 13.

Abstract

Introduction: Infantile leukemia encompasses a heterogeneous group which needs stratifying for treatment selection.

Methods: We collected 78 cases of infantile leukemia and retrospectively analyzed their clinicopathological data.

Results: Infantile leukemia featured a ratio of acute myeloid leukemia (AML) to B-lymphoblastic leukemia (B-ALL) of 1:2, with a better survival for AML than B-ALL (median survival 36 vs 24 months). When stratified by age, "early" infantile B-ALL (2-6 months) showed a high rate of KMT2A rearrangement (100%), similar to the rate seen in congenital B-ALL (1 month) (100%) and higher than seen in "late" infantile B-ALL (≥7 months) (68%). The three categories of infantile B-ALL exhibited an age-dependent increase in survival (median survival 8.5, 24, and >24 months, respectively). The age-dependent survival benefit remained after excluding the cases negative for KMT2A rearrangement. Conversely, infantile AML lacked an age-dependent pattern of survival.

Conclusion: The clinical outcome of infantile leukemia depends on the type of leukemia. Given the age-dependent survival, infantile B-ALL can be divided into three subcategories.

Keywords: B-lymphoblastic leukemia; acute myeloid leukemia; congenital leukemia; infantile leukemia.

MeSH terms

  • Female
  • Gene Rearrangement
  • Histone-Lysine N-Methyltransferase / genetics
  • Humans
  • Infant
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / pathology*
  • Male
  • Myeloid-Lymphoid Leukemia Protein / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology*
  • Retrospective Studies

Substances

  • KMT2A protein, human
  • Myeloid-Lymphoid Leukemia Protein
  • Histone-Lysine N-Methyltransferase